GLP-1 agonists, including semaglutide and tirzepatide, are emerging as powerful tools in the fight against obesity, type 2 diabetes, and cardiovascular disease. These medications not only help regulate blood sugar and hunger hormones but also offer promising anti-inflammatory effects, which may reduce risks for certain cancers and neurodegenerative diseases. Dr. Griffin views these medications as empowering tools, helping patients take control of their health through weight management and disease prevention.
